Skip to main content
Premium Trial:

Request an Annual Quote

EncrypGen Partners With Health Wizz, Codigo46

NEW YORK (GenomeWeb) – EncrypGen, which specializes in blockchain for the genetic market, today announced strategic partnerships with Health Wizz and Codigo46.

Under the first partnership, EncrypGen and Health Wizz will work together to integrate EncrypGen's Gene-Chain product — a private, permissioned blockchain for the secure transmission of de-identified genetic data — into the Health Wizz mobile platform, which provides consumers with tools to aggregate, manage, and share their medical data.

As part of the second partnership, EncrypGen will sell Codigo46's genetic testing through the preferred vendor section of the EncrypGen website. The Codigo46 report is based on a non-invasive test that uses a buccal swab to obtain and analyze customers' DNA to provide personalized information about disease risk, pharmacogenomics, and ancestry.

"Both developments are in anticipation of our imminent 'MyGene-Chain' service, which enables people to take control of their genomic data from testing to storage and to share it with their physicians," EncrypGen CEO David Koepsell said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.